INCOME TAXES (Effective Tax Rate Reconciliation) (Details) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Earnings from continuing operations before income taxes [Abstract]
U.S. earnings before income taxes	$ (271)	$ 4,336	$ 3,833
Non-U.S. earnings before income taxes	2,611	2,645	2,238
Earnings Before Income Taxes	2,340	6,981	6,071
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
U.S statutory income tax rate	35.00%	35.00%	35.00%
Non-tax deductible annual pharmaceutical company fee, rate	3.80%	1.20%
Tax effect of foreign subsidiaries' earnings previously considered indefinitely reinvested offshore, rate			3.40%
Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland, rate	(29.40%)	(8.50%)	(11.40%)
State and local taxes (net of valuation allowance), rate	0.90%	0.50%	0.70%
U.S. Federal, state and foreign contingent tax matters, rate	2.80%	(2.30%)	(2.10%)
U.S. Federal research and development tax credit, rate		(1.00%)	(1.00%)
U.S. tax effect of capital losses, rate	(16.70%)
Foreign and other, rate	(3.30%)	(0.20%)	1.10%
Effective income tax rate	(6.90%)	24.70%	25.70%
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
U.S. statutory rate, amount	819	2,443	2,125
Non-tax deductible annual pharmaceutical company fee	90	80
Tax effect of foreign subsidiaries' earnings previously considered indefinitely reinvested offshore, amount			207
Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland, amount	(688)	(593)	(694)
State and local taxes (net of valuation allowance), amount	20	33	43
U.S. Federal, state and foreign contingent tax matters	66	(161)	(131)
U.S. Federal research and development tax credit, amount		(69)	(61)
U.S. tax effect of capital losses	(392)
Foreign and other, amount	(76)	(12)	69
Income Tax Expense (Benefit), Total	(161)	1,721	1,558
Out-of-period tax adjustment related to previously unrecognized net deferred tax assets primarily attributed to deferred profits related to certain alliances			59
Tax benefit/charge from finalizing U.S. tax return		$ 54	$ 30